Grass Pollen Allergy - Pipeline Review, H2 2016

Choose Licence

 

Grass Pollen Allergy - Pipeline Review, H2 2016 Summary Global Markets Directs, Grass Pollen Allergy - Pipeline Review, H2 2016?, provides an overview of the Grass Pollen Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy - The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects - The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Grass Pollen Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Grass Pollen Allergy - Overview 7 Grass Pollen Allergy - Therapeutics under Development by Companies 8 Grass Pollen Allergy - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Grass Pollen Allergy - Products under Development by Companies 11 Grass Pollen Allergy - Companies Involved in Therapeutics Development 12 ALK-Abello A/S 12 Allergy Therapeutics Plc 13 Biomay AG 14 Circassia Pharmaceuticals Plc 15 HAL Allergy BV 16 Roxall Medizin GmbH 17 Shionogi & Co., Ltd. 18 Grass Pollen Allergy - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 asapiprant - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BM-32 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 clustoid wiesenlieschgras - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Pollinex Quattro Grass - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Grass Pollen Allergy - Dormant Projects 42 Grass Pollen Allergy - Product Development Milestones 43 Featured News & Press Releases 43 Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 43 Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children 43 May 25, 2016: Circassia Initiates Grass Allergy Immunotherapy Registration Study 45 Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 46 Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32 47 Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children 47 Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 48 Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 49 Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 49 Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 50 Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 51 Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 51 Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 51 Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 52 Nov 09, 2013: Merck?s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56

List of Tables Number of Products under Development for Grass Pollen Allergy, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016 12 Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016 13 Grass Pollen Allergy - Pipeline by Biomay AG, H2 2016 14 Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 15 Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016 16 Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2016 17 Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Grass Pollen Allergy - Dormant Projects, H2 2016 42


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports